Metabolic deterioration of the sedentary control group in clinical trials

被引:7
|
作者
Patel, Mahesh J. [1 ]
Slentz, Cris A. [1 ]
Kraus, William E. [1 ]
机构
[1] Duke Univ, Med Ctr, Div Cardiovasc Med, Durham, NC 27710 USA
关键词
physical inactivity; DENSITY-LIPOPROTEIN-CHOLESTEROL; RISK REDUCTION INTERVENTION; EXERCISE TRAINING AMOUNT; CORONARY-HEART-DISEASE; ALL-CAUSE MORTALITY; PHYSICAL-ACTIVITY; SKELETAL-MUSCLE; VISCERAL FAT; BODY-WEIGHT; INTENSITY;
D O I
10.1152/japplphysiol.00421.2011
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
Patel MJ, Slentz CA, Kraus WE. Metabolic deterioration of the sedentary control group in clinical trials. J Appl Physiol 111: 1211-1217, 2011. First published July 21, 2011; doi:10.1152/japplphysiol.00421.2011.-Randomized clinical trials of exercise training regimens in sedentary individuals have provided a mechanistic understanding of the long-term health benefits and consequences of physical activity and inactivity. The sedentary control periods from these trials have provided evidence of the progressive metabolic deterioration that results from as little as 4-6 mo of continuing a physically inactive lifestyle. These clinical trials have also demonstrated that only a modest amount of physical activity is required to prevent this metabolic deterioration, and this amount of physical activity is consistent with current physical activity recommendations (150 min/wk of moderate intensity physical activity). These recommendations have been issued to the general population for a vast array of health benefits. While greater adherence to these recommendations should result in substantial improvements in the health of the population, these recommendations still remain inadequate for many individuals. An individual's physical activity requirements are influenced by such factors as an individual's diet, nonexercise physical activity patterns, genetic profile, and medications. Improving the understanding of how these factors influence an individual's physical activity requirements will help advance the field and help move the field toward the development of more personalized physical activity recommendations.
引用
收藏
页码:1211 / 1217
页数:7
相关论文
共 50 条
  • [1] Determinants of control group choice in clinical trials
    Gold, Stefan
    INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE, 2021, 28 (SUPPL 1) : S47 - S47
  • [2] Better conduct of clinical trials: The control group in critical care trials
    Takala, Jukka
    CRITICAL CARE MEDICINE, 2009, 37 (01) : S80 - S90
  • [3] Cooperative Group Cancer Clinical Trials: An NCIC Clinical Trials Group Perspective
    Meyer, Ralph M.
    Stanton, Heather A.
    Parulekar, Wendy R.
    Saad, Fred
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2011, 5 (06): : 379 - 381
  • [4] Simulated Electroconvulsive Therapy A Novel Approach to a Control Group in Clinical Trials
    McManus, Kaitlin R.
    Lapid, Maria, I
    Forester, Brent P.
    Mueller, Martina
    Hermida, Adriana P.
    Nykamp, Louis
    Harper, David G.
    Seiner, Stephen J.
    Sanghani, Sohag
    Patrick, Regan
    Gentry, Melanie T.
    Kung, Simon
    Leal, Janette C.
    Johnson, Emily K.
    Petrides, Georgios
    JOURNAL OF ECT, 2022, 38 (03) : 165 - 170
  • [5] Positive clinical trials - Understand the control group before implementing the result
    Parshuram, CS
    Kavanagh, BP
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 170 (03) : 223 - 226
  • [6] Clinical trials: Specific problems associated with the use of a placebo control group
    Cleophas, TJM
    VonderMeulen, J
    Kalmansohn, RB
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 43 (03) : 219 - 221
  • [7] Design of control-group conditions in clinical trials of behavioral interventions
    Lindquist, Ruth
    Wyman, Jean F.
    Talley, Kristine M. C.
    Findorff, Mary J.
    Gross, Cynthia R.
    JOURNAL OF NURSING SCHOLARSHIP, 2007, 39 (03) : 214 - 221
  • [8] Clinical Trials: A Need to Better Define the Control Group as Current Standard of Care
    Bakri, Sophie J.
    OPHTHALMOLOGY, 2015, 122 (03) : 443 - 444
  • [9] The control group dilemma in clinical research: Applications for psychosocial and behavioral medicine trials
    Schwartz, CE
    Chesney, MA
    Irvine, MJ
    Keefe, FJ
    PSYCHOSOMATIC MEDICINE, 1997, 59 (04): : 362 - 371
  • [10] Influence of control group design on outcome in recent antipsychotic clinical trials for schizophrenia
    Woods, SW
    Gueorguieva, RV
    Makuch, RW
    SCHIZOPHRENIA RESEARCH, 2002, 53 (03) : 20 - 20